An Oncogenomics-Based In Vivo RNAi Screen Identifies Tumor Suppressors in Liver Cancer

[1]  V. Velculescu.  Defining the blueprint of the cancer genome. , 2008, Carcinogenesis.

[2]  A. Krasnitz,et al.  DLC1 is a chromosome 8p tumor suppressor whose loss promotes hepatocellular carcinoma. , 2008, Genes & development.

[3]  Joe W. Gray,et al.  Translating insights from the cancer genome into clinical practice , 2008, Nature.

[4]  Yoshihiro Kakeji,et al.  Deregulation of the Akt pathway in human cancer. , 2008, Current cancer drug targets.

[5]  S. Warren,et al.  Replication stress induces tumor-like microdeletions in FHIT/FRA3B , 2008, Proceedings of the National Academy of Sciences.

[6]  A. Sparks,et al.  The Genomic Landscapes of Human Breast and Colorectal Cancers , 2007, Science.

[7]  Jude Kendall,et al.  Oncogenic cooperation and coamplification of developmental transcription factor genes in lung cancer , 2007, Proceedings of the National Academy of Sciences.

[8]  Wen-Lin Kuo,et al.  Amplification of PVT1 Contributes to the Pathophysiology of Ovarian and Breast Cancer , 2007, Clinical Cancer Research.

[9]  A. Berns,et al.  p15Ink4b is a critical tumour suppressor in the absence of p16Ink4a , 2007, Nature.

[10]  W. Birchmeier,et al.  The transcriptional repressor Glis2 is a novel binding partner for p120 catenin. , 2007, Molecular biology of the cell.

[11]  E. Birney,et al.  Patterns of somatic mutation in human cancer genomes , 2007, Nature.

[12]  Carlos Cordon-Cardo,et al.  Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas , 2007, Nature.

[13]  W. Birchmeier,et al.  The Transcriptional Repressor Glis 2 Is a Novel Binding Partner for p 120 Catenin , 2007 .

[14]  I. Tomlinson,et al.  Colorectal cancer and genetic alterations in the Wnt pathway , 2006, Oncogene.

[15]  Kenny Q. Ye,et al.  Novel patterns of genome rearrangement and their association with survival in breast cancer. , 2006, Genome research.

[16]  S. Baker,et al.  PTEN function in normal and neoplastic growth. , 2006, Cancer letters.

[17]  M. Wigler,et al.  Identification and Validation of Oncogenes in Liver Cancer Using an Integrative Oncogenomic Approach , 2006, Cell.

[18]  S. Thorgeirsson,et al.  Comparative and integrative functional genomics of HCC , 2006, Oncogene.

[19]  H. E. Johansson,et al.  Differential expression of eIF5A‐1 and eIF5A‐2 in human cancer cells , 2006, The FEBS journal.

[20]  C. Heldin,et al.  The Mechanism of Nuclear Export of Smad3 Involves Exportin 4 and Ran , 2006, Molecular and Cellular Biology.

[21]  S. Lowe,et al.  Probing tumor phenotypes using stable and regulated synthetic microRNA precursors , 2005, Nature Genetics.

[22]  Patrick J. Paddison,et al.  Second-generation shRNA libraries covering the mouse and human genomes , 2005, Nature Genetics.

[23]  S. Kloeker,et al.  TGF-β inhibitors for the treatment of cancer , 2005 .

[24]  J. Woodgett,et al.  The links between axin and carcinogenesis , 2005, Journal of Clinical Pathology.

[25]  S. Kloeker,et al.  TGF-beta inhibitors for the treatment of cancer. , 2005, Expert opinion on investigational drugs.

[26]  R. Lucito,et al.  Generation and analysis of genetically defined liver carcinomas derived from bipotential liver progenitors. , 2005, Cold Spring Harbor symposia on quantitative biology.

[27]  T. Mak,et al.  Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. , 2004, The Journal of clinical investigation.

[28]  D. Xie,et al.  Oncogenic Role of eIF-5A2 in the Development of Ovarian Cancer , 2004, Cancer Research.

[29]  Pamela A. Silver,et al.  Nuclear transport and cancer: from mechanism to intervention , 2004, Nature Reviews Cancer.

[30]  J. Hershey,et al.  Identification and characterization of eukaryotic initiation factor 5A-2. , 2003, European journal of biochemistry.

[31]  J. Sebat,et al.  Representational oligonucleotide microarray analysis: a high-resolution method to detect genome copy number variation. , 2003, Genome research.

[32]  Patrick J. Paddison,et al.  An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo , 2003, Nature Genetics.

[33]  S. Lowe,et al.  Dissecting p53 tumor suppressor functions in vivo. , 2002, Cancer cell.

[34]  T. Jacks,et al.  Cancer Modeling in the Modern Era Progress and Challenges , 2002, Cell.

[35]  X. Guan,et al.  Isolation of a novel candidate oncogene within a frequently amplified region at 3q26 in ovarian cancer. , 2001, Cancer research.

[36]  M. Marra,et al.  The role of eukaryotic initiation factor 5A in the control of cell proliferation and apoptosis , 2001, Amino Acids.

[37]  G. Lipowsky,et al.  Exportin 4: a mediator of a novel nuclear export pathway in higher eukaryotes , 2000, The EMBO journal.

[38]  M. Buendia.  Genetics of hepatocellular carcinoma. , 2000, Seminars in cancer biology.

[39]  N. Copeland,et al.  Title Structure , Expression , and Chromosome Mapping of LATS 2 , a Mammalian Homologue of the Drosophila Tumor Suppressor Gene lats / warts , 2022 .

[40]  J. Massagué.  How cells read TGF-beta signals. , 2000, Nature reviews. Molecular cell biology.

[41]  M. H. Park,et al.  Antiproliferative effects of inhibitors of deoxyhypusine synthase. Inhibition of growth of Chinese hamster ovary cells by guanyl diamines. , 1994, The Journal of biological chemistry.

[42]  M. Fornerod,et al.  Translocation t(6;9) in acute non-lymphocytic leukaemia results in the formation of a DEK-CAN fusion gene. , 1992, Bailliere's clinical haematology.

[43]  R. Benne,et al.  The mechanism of action of protein synthesis initiation factors from rabbit reticulocytes. , 1978, The Journal of biological chemistry.